---
title: "CIRSE 2025: SAVE trial reports higher efficacy for Selution SLR DEB in failing AVF"
date: "2025-09-15T07:48:35.000Z"
publishedDate: "15 septembre 2025"
summary: "A first report from the SAVE prospective, multicentre, single-blinded randomised controlled trial of the Selution sustained limus release (SLR; Cordis) drug-eluting balloon (DEB) in patients with failing arteriovenous fistula (AVF) undergoing haemodialysis has demonstrated “significantly higher efficacy” compared with plain balloon angioplasty, with a higher target lesion primary patency (TLPP) at six-month follow-up. Konstantinos Katsanos [&#8230;] The post CIRSE 2025: SAVE trial reports higher efficacy for Selution SLR DEB in failing AVF appeared first on Vascular News ."
importance: ""
sourceUrl: "https://vascularnews.com/cirse-2025-save-trial-reports-higher-efficacy-for-selution-slr-deb-in-failing-avf/"
tags: ["France", "Actualité", "Vascular News — Latest"]
permalink: "/papers/2025-09-15-cirse-2025-save-trial-reports-higher-efficacy-for-selution-slr-deb-in-failing-avf"
imageUrl: "https://vascularnews.com/wp-content/uploads/sites/7/2025/09/Image-19.jpeg"
imageCredit: "Image de l’article — droits possiblement réservés — https://vascularnews.com/cirse-2025-save-trial-reports-higher-efficacy-for-selution-slr-deb-in-failing-avf/"
---

![CIRSE 2025: SAVE trial reports higher efficacy for Selution SLR DEB in failing AVF](https://vascularnews.com/wp-content/uploads/sites/7/2025/09/Image-19.jpeg)

*Crédit image : Image de l’article — droits possiblement réservés — https://vascularnews.com/cirse-2025-save-trial-reports-higher-efficacy-for-selution-slr-deb-in-failing-avf/*

## L’essentiel

A first report from the SAVE prospective, multicentre, single-blinded randomised controlled trial of the Selution sustained limus release (SLR; Cordis) drug-eluting balloon (DEB) in patients with failing arteriovenous fistula (AVF) undergoing haemodialysis has demonstrated “significantly higher efficacy” compared with plain balloon angioplasty, with a higher target lesion primary patency (TLPP) at six-month follow-up. Konstantinos Katsanos [&#8230;] The post CIRSE 2025: SAVE trial reports higher efficacy for Selution SLR DEB in failing AVF appeared first on Vascular News .

## Lien source

https://vascularnews.com/cirse-2025-save-trial-reports-higher-efficacy-for-selution-slr-deb-in-failing-avf/
